Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 17/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177889 | 0.94 | HTR4 (0.56) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Hydrochloric Acid SCHEMBL6765846 | 0.93 | HTR4 (0.55) | HTR4HTR1AADRA2CACHEPTGS1 | |
| SCHEMBL6176127 | 0.90 | HTR4 (0.59) | HTR4HTR1AADRA2CACHEPTGS1 | |
| SCHEMBL6180780 | 0.88 | KCNH2 (0.60) | HTR4HTR3AKCNH2 | |
| Hydrochloric Acid SCHEMBL6770784 | 0.87 | KCNH2 (0.59) | HTR4HTR3AKCNH2 | |
| SCHEMBL6179363 | 0.84 | HTR4 (0.60) | HTR4HTR1AADRA2CACHEPTGS1 | |
| SCHEMBL6767167 | 0.80 | KCNH2 (0.62) | HTR4HTR3AKCNH2 | |
| SCHEMBL6177801 | 0.79 | HTR4 (0.49) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Hydrochloric Acid SCHEMBL6764321 | 0.78 | HTR4 (0.48) | HTR4HTR1AADRA2CACHEPTGS1 | |
| SCHEMBL6177604 | 0.78 | KCNH2 (0.74) | HTR4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR4 1/4885HTR1A 14/4885ADRA2C 92/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | HTR4 2/4885HTR1A 14/4885ADRA2C 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.